CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...

CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

FIRDAPSE (amifampridine) is the only U.S. FDA approved, evidence-based therapy for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder ...

Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin ...

Amifampridine phosphate was granted orphan drug designation by the Ministry of Health, Labor, and Welfare in Japan, and FIRDAPSE has previously been approved for use in the U.S. in adults and ...

(MENAFN- GlobeNewsWire - Nasdaq) As Part of the Settlement, Teva Receives a License to market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE ...

CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...